These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 21466592)

  • 1. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.
    Skandalis K; Spirova M; Gaitanis G; Tsartsarakis A; Bassukas ID
    J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):249-53. PubMed ID: 21466592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of bullous pemphigoid ınduced by vildagliptin.
    Keseroglu HO; Taş-Aygar G; Gönül M; Gököz O; Ersoy-Evans S
    Cutan Ocul Toxicol; 2017 Jun; 36(2):201-202. PubMed ID: 27460861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bullous pemphigoid induced by vildagliptin: a report of three cases.
    Béné J; Jacobsoone A; Coupe P; Auffret M; Babai S; Hillaire-Buys D; Jean-Pastor MJ; Vonarx M; Vermersch A; Tronquoy AF; Gautier S
    Fundam Clin Pharmacol; 2015 Feb; 29(1):112-4. PubMed ID: 24861252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Tasanen K; Varpuluoma O; Nishie W
    Front Immunol; 2019; 10():1238. PubMed ID: 31275298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gliptin-Induced Bullous Pemphigoid: Canadian Case Series of 10 Patients.
    Armanious M; AbuHilal M
    J Cutan Med Surg; 2021; 25(2):163-168. PubMed ID: 33176433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin + metformin: new combination. Do not use this combination. Sitagliptin provides a slight increase of glucose-lowering effects, but there is a disturbing potential for long-term adverse effects: infections, depression, and cancer.
    Prescrire Int; 2009 Jun; 18(101):115. PubMed ID: 19637427
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
    Kridin K; Bergman R
    JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor - A case report.
    Karthik S; Joseph PE; Babu T
    J Postgrad Med; 2019; 65(4):244-246. PubMed ID: 31535624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.
    Lambadiari V; Kountouri A; Kousathana F; Korakas E; Kokkalis G; Theotokoglou S; Palaiodimou L; Katsimbri P; Ikonomidis I; Theodoropoulos K; Papadavid E
    BMC Endocr Disord; 2021 Feb; 21(1):23. PubMed ID: 33573656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
    Scherbaum WA
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
    [No Abstract]   [Full Text] [Related]  

  • 12. Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases.
    Jha A; Misra A; Gupta R; Ghosh A; Tyagi K; Dutta K; Arora B; Durani S
    Diabetes Metab Syndr; 2020; 14(3):213-216. PubMed ID: 32172176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population.
    Plaquevent M; Tétart F; Fardet L; Ingen-Housz-Oro S; Valeyrie-Allanore L; Bernard P; Hebert V; Roussel A; Avenel-Audran M; Chaby G; D'Incan M; Ferrier-Le-Bouedec MC; Duvert-Lehembre S; Picard-Dahan C; Jeudy G; Collet E; Labeille B; Morice C; Richard MA; Bourgault-Villada I; Litrowski N; Bara C; Mahe E; Prost-Squarcioni C; Alexandre M; Quereux G; Bernier C; Soria A; Thomas-Beaulieu D; Pauwels C; Dereure O; Benichou J; Joly P; ;
    J Invest Dermatol; 2019 Apr; 139(4):835-841. PubMed ID: 30543900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes.
    Prescrire Int; 2008 Oct; 17(97):188. PubMed ID: 19534040
    [No Abstract]   [Full Text] [Related]  

  • 15. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
    Benzaquen M; Borradori L; Berbis P; Cazzaniga S; Valero R; Richard MA; Feldmeyer L
    J Am Acad Dermatol; 2018 Jun; 78(6):1090-1096. PubMed ID: 29274348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients.
    Nätynki A; Leisti P; Tuusa J; Varpuluoma O; Huilaja L; Izumi K; Herukka SK; Ukkola O; Junttila J; Kokkonen N; Tasanen K
    Front Immunol; 2022; 13():942131. PubMed ID: 35958564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in a patient with acquired reactive perforating collagenosis.
    Maki N; Nishie W; Takazawa M; Kakurai M; Yamada T; Umemoto N; Kawase M; Izumi K; Shimizu H; Demitsu T
    J Dermatol; 2018 May; 45(5):600-602. PubMed ID: 29446164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes.
    Rosenstock J; Lewin AJ; Norwood P; Somayaji V; Nguyen TT; Teeter JG; Johnson SL; Dai H; Terra SG
    Diabet Med; 2011 Apr; 28(4):464-9. PubMed ID: 21392067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of musculoskeletal complaints and gliptin use: review of spontaneous reports.
    Tarapués M; Cereza G; Figueras A
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1115-8. PubMed ID: 23960039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.